The bladder cancer: the risk factors and prognostic markers

  • O. N. Sulayeva Pathomorphological Laboratory «CSD Health Care», Kyiv http://orcid.org/0000-0002-9614-4652
  • A. A. Seleznev Pathomorphological Laboratory «CSD Health Care», Kyiv
  • R. N. Ponomarchuk Pathomorphological Laboratory «CSD Health Care», Kyiv
  • A. E. Stakhovskyi National Cancer Institute, Kyiv
  • D. A. Shapochka Pathomorphological Laboratory «CSD Health Care», Kyiv

Abstract

The bladder cancer: the risk factors and prognostic markers

Author Biographies

O. N. Sulayeva, Pathomorphological Laboratory «CSD Health Care», Kyiv

Oksana Sulaieva- MD, DSci, Professor, Scientific Director,
Laboratory of Pathology “CSD Health Care”,
Vasylkivska street, 45.
Phone: +380675136843.
Emai: o.sulaieva@csd.com.ua;
http://orcid.org/0000-0002-9614-4652

A. A. Seleznev, Pathomorphological Laboratory «CSD Health Care», Kyiv

Selesnov Oleksiy - MD, PhD, Associate Profeccor, Pathologist,
Laboratory of Pathology “CSD Health Care”,
Vasylkivska street, 45.
Phone: +380675136843.
Email: oleksii.seleznov@csd.com.ua

R. N. Ponomarchuk, Pathomorphological Laboratory «CSD Health Care», Kyiv

Ponomarchuk Roman - MD, Pathologist,
Laboratory of Pathology “CSD Health Care”,
Vasylkivska street, 45.
Phone: +380675136843.
Email: r.ponomarchuk@csd.com.ua

A. E. Stakhovskyi, National Cancer Institute, Kyiv

Stakhovskyi Oleksandr - MD, PhD, senior researcher,
devision of Plastic and reconstructive oncourology,
National Cancer Institute, Kyiv, Lomonosova street 33/43.
Phone: +380503817217.
Email: stakhovsky9@gmail.com

D. A. Shapochka, Pathomorphological Laboratory «CSD Health Care», Kyiv

Shapochka Dmytro, Pathologist,
Laboratory of Pathology “CSD Health Care”,
Vasylkivska street, 45.
Phone: +380675136843.
Email: d.shapochka@csd.com.ua

References

Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, et al. Bladder cancer. J Natl Compr Cancer Netw. 2013;11(4):446-75.doi: 10.6004/jnccn.2013.0059.

Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer incidence and mortality: a global overview and recent trends.Eur Urol.2017;71(1):96-108.doi: 10.1016/j.eururo.2016.06.010.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492.

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22. doi: 10.1038/nature12965.

Bostwick DG, Cheng L. Urologic Surgical Pathology. 3rd ed. Philadelphia, PA: Elsevier/Saunders; 2014. 976 p.

Janković S, Radosavljević V. Risk factors for bladder cancer. Tumori. 2007;93(1):4-12.PMID:17455864.

Matulay JT, Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Res. 2018;7. pii: F1000 Faculty Rev-1137. doi: 10.12688/f1000research.14903.1.

Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25(3):285-95. doi: 10.1007/s00345-007-0168-5.

Hemelt M, Yamamoto H, Cheng KK, Zeegers MPA. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer. 2009;124(2):412-9. doi: 10.1002/ijc.23856.

Ferrís J, Berbel O, Alonso-López J, Garcia J, Ortega JA. Environmental non-occupational risk factors associated with bladder cancer. ActasUrol Esp. 2013;37(9):579-86. doi: 10.1016/j.acuro.2013.02.004.

Al-Zalabani AH, Stewart KFJ, Wesselius A, Schols AMWJ, Zeegers MP. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. Eur J Epidemiol. 2016;31(9):811-51. doi: 10.1007/s10654-016-0138-6.

Babjuk M, Bohle A, Burger M. EAU guidelines on nonmuscleinvasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447-61.doi: 10.1016/j.eururo.2016.05.041.

Hansel DE, Miller JS, Cookson MS, Chang SS. Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist. Urology. 2013;81(6):1123-30. doi: 10.1016/j.urology.2013.01.027.

Traboulsi SL, Brimo F, Yang Y, Maedler C, Prévost N, Tanguay S, et al. Pathology review impacts clinical management of patients with T1-T2 bladder cancer. Can Urol Assoc J. 2017;11(6):188-93. doi: 10.5489/cuaj.4126.

Ku JH, Yuk HD, Godoy G, Amiel GE, Lerner SP. Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants. Bladder Cancer. 2018;4(2):195-203. doi: 10.3233/BLC-170156.

Kobayashi T. Understanding the biology of urothelial cancer metastasis. Asian J Urol. 2016;3(4):211-22. doi: 10.1016/j.ajur.2016.09.005.

Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251-85. doi: 10.1146/annurev.pathol.4.110807.092230.

Rentsch CA, Müller DC, Ruiz C, Bubendorf L. Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation? Eur Urol. 2017;72(6):960-1. doi: 10.1016/j.eururo.2017.06.022.

Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22(S2):S96-S118. doi: 10.1038/modpathol.2009.26.

Baumeister P, Zamboni S, Mattei A, Antonelli A, Simeone C, Mordasini L. et al. Histological variants in non-muscle invasive bladder cancer. TranslAndrol Urol. 2019;8(1):34-8. doi: 10.21037/tau.2019.01.09.

Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. Geneva, Switserland: WHO Press; 2016.

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70(1):106-19. doi: 10.1016/j.eururo.2016.02.028.

KimJK, MoonKC, JeongCW, KwakC, KimHH, KuJH. Papillary urothelial neoplasm of low malignant potential (PUNLMP) after initial TUR-BT: comparative analyses with noninvasive low-grade papillary urothelial carcinoma (LGPUC). J Cancer. 2017;8(15):2885-91.doi: 10.7150/jca.20003.

Kvikstad V, Mangrud OM, Gudlaugsson E, Dalen I, Espeland H, Baak JPA, et al. Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas. Diagn Pathol. 2019;14(1):90. doi: 10.1186/s13000-019-0868-3.

Li G, Yu J, Song H, Zhu S, Sun L, Shang Z, et al. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. BMC Cancer. 2017;17(1):530. doi: 10.1186/s12885-017-3520-1.

Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016".Eur Urol Focus. 2019;5(3):457-66. doi: 10.1016/j.euf.2018.01.003.

Jimenez RE, Gheiler E, Oskanian P, Tiguert R, Sakr W, Wood DP Jr, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol. 2000;24(7):980-7.doi: 10.1097/00000478-200007000-00009.

Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages ta, T1 urothelial carcinoma of the bladder. J Urol. 2003;169(4):1291-4. doi: 10.1097/01.ju.0000055471.78783.ae.

Garg M. Epithelial plasticity in urothelial carcinoma: Current advancements and future challenges. World J Stem Cells. 2016;8(8):260-7. doi: 10.4252/wjsc.v8.i8.260.

Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, et al editors. AJCC Cancer Staging Manual. 8th editional.Chicago: Springer; 2017.

Oszczudlowski M, Dobruch J. Prediction of progression to muscle-invasive disease in patients with high-risk bladder cancer. TranslAndrol Urol. 2018;7(4):749-51. doi: 10.21037/tau.2018.06.14.

Saito K, Kawakami S, Fujii Y, Sakura M, Masuda H, Kihara K. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. JUrol. 2007;178(6):2291-6. doi:10.1016/j.juro.2007.08.019.

Published
2019-12-20
How to Cite
Sulayeva, O. N., Seleznev, A. A., Ponomarchuk, R. N., Stakhovskyi, A. E., & Shapochka, D. A. (2019). The bladder cancer: the risk factors and prognostic markers. Klinicheskaia Khirurgiia, 86(11-12), 78-84. https://doi.org/10.26779/2522-1396.2019.11-12.78